These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 27031684)

  • 21. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
    Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
    J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient.
    Hu W; Chen A; Miao Y; Xia S; Ling Z; Xu K; Wang T; Xu Y; Cui J; Wu H; Hu G; Tian L; Wang L; Shu Y; Ma X; Xu B; Zhang J; Lin X; Bian C; Sun B
    Virology; 2013 Jan; 435(2):320-8. PubMed ID: 23084424
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Sutton TC; Lamirande EW; Bock KW; Moore IN; Koudstaal W; Rehman M; Weverling GJ; Goudsmit J; Subbarao K
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29046448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
    Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
    Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A highly conserved neutralizing epitope on group 2 influenza A viruses.
    Ekiert DC; Friesen RH; Bhabha G; Kwaks T; Jongeneelen M; Yu W; Ophorst C; Cox F; Korse HJ; Brandenburg B; Vogels R; Brakenhoff JP; Kompier R; Koldijk MH; Cornelissen LA; Poon LL; Peiris M; Koudstaal W; Wilson IA; Goudsmit J
    Science; 2011 Aug; 333(6044):843-50. PubMed ID: 21737702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris.
    Wang SC; Liao HY; Zhang JY; Cheng TR; Wong CH
    Virology; 2019 Jan; 526():125-137. PubMed ID: 30388628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
    Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.
    Kanekiyo M; Joyce MG; Gillespie RA; Gallagher JR; Andrews SF; Yassine HM; Wheatley AK; Fisher BE; Ambrozak DR; Creanga A; Leung K; Yang ES; Boyoglu-Barnum S; Georgiev IS; Tsybovsky Y; Prabhakaran MS; Andersen H; Kong WP; Baxa U; Zephir KL; Ledgerwood JE; Koup RA; Kwong PD; Harris AK; McDermott AB; Mascola JR; Graham BS
    Nat Immunol; 2019 Mar; 20(3):362-372. PubMed ID: 30742080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An H1N1 Computationally Optimized Broadly Reactive Antigen Elicits a Neutralizing Antibody Response against an Emerging Human-Infecting Eurasian Avian-Like Swine Influenza Virus.
    Sautto GA; Ecker JW; Ross TM
    J Virol; 2021 Jun; 95(13):e0242120. PubMed ID: 33853960
    [No Abstract]   [Full Text] [Related]  

  • 30. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies.
    Kanekiyo M; Wei CJ; Yassine HM; McTamney PM; Boyington JC; Whittle JR; Rao SS; Kong WP; Wang L; Nabel GJ
    Nature; 2013 Jul; 499(7456):102-6. PubMed ID: 23698367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.
    Cheong Y; Kim M; Ahn J; Oh H; Lim J; Chae W; Yang SW; Kim MS; Yu JE; Byun S; Jang YH; Seong BL
    Front Immunol; 2021; 12():769088. PubMed ID: 34868027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.
    Wang W; Vassell R; Song HS; Chen Q; Keller PW; Verma S; Alvarado-Facundo E; Wan H; Schmeisser F; Meseda CA; Weir JP; Weiss CD
    PLoS One; 2019; 14(9):e0222436. PubMed ID: 31513662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
    Settembre EC; Dormitzer PR; Rappuoli R
    J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
    Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
    Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
    J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of protective immunity against influenza A/Jiangxi-Donghu/346/2013 (H10N8) in mice.
    Kuah LF; Tang LH; Sutton T; Lim JH; Sin WL; Lamirande E; Subbarao K; Lau YF
    J Gen Virol; 2017 Feb; 98(2):155-165. PubMed ID: 27983474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.
    Nagashima KA; Mousa JJ
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33805245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.
    Zost SJ; Wu NC; Hensley SE; Wilson IA
    J Infect Dis; 2019 Apr; 219(Suppl_1):S38-S45. PubMed ID: 30535315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
    Henry Dunand CJ; Leon PE; Huang M; Choi A; Chromikova V; Ho IY; Tan GS; Cruz J; Hirsh A; Zheng NY; Mullarkey CE; Ennis FA; Terajima M; Treanor JJ; Topham DJ; Subbarao K; Palese P; Krammer F; Wilson PC
    Cell Host Microbe; 2016 Jun; 19(6):800-13. PubMed ID: 27281570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.
    Krammer F; Pica N; Hai R; Margine I; Palese P
    J Virol; 2013 Jun; 87(12):6542-50. PubMed ID: 23576508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.